Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alsoKnownAs |
gptkb:Niraparib
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:cancer
gptkb:FDA |
| gptkbp:ATCCode |
L01XX60
|
| gptkbp:brand |
gptkb:Zejula
|
| gptkbp:CASNumber |
1038915-60-4
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Tesaro
|
| gptkbp:hasMolecularFormula |
C19H20N4O
|
| gptkbp:hasSMILES |
CC1=NN=C(N1C2=CC=CC=C2)C3=CC=CC=C3C(=O)N4CCNCC4
|
| https://www.w3.org/2000/01/rdf-schema#label |
SF-2281
|
| gptkbp:indication |
maintenance treatment of recurrent ovarian cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits poly ADP ribose polymerase (PARP)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1800631
gptkb:DB11709 24958200 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea constipation fatigue insomnia thrombocytopenia |
| gptkbp:target |
gptkb:PARP1
gptkb:PARP2 |
| gptkbp:UNII |
KXJ3Q6N1GA
|
| gptkbp:usedAs |
PARP inhibitor
|
| gptkbp:bfsParent |
gptkb:SandForce_SSD_controllers
|
| gptkbp:bfsLayer |
6
|